COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs and Tests
Executive Summary
Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.
You may also be interested in...
MPP Strikes Deal For Long-Acting Injectable HIV Candidate
The University of Washington has agreed to license an in-development HIV treatment to the Medicines Patent Pool, which takes the form of a monthly subcutaneous injection instead of daily oral treatment.
Coronavirus Notebook: BARDA Contracting Scrutiny; Part D Cost Sharing
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
Should Pharma Release IP For COVID-19 Research? Novartis Exec Weighs In
As World Health Assembly prepares resolution for voluntary pooling and licensing, Novartis global head of IP Corey Salsberg discusses how intellectual property is advancing development of therapeutics and vaccines and the benefits of voluntary rather than compulsory licensing;